$GNPX
Genprex Inc Stock $gnpx

$gnpx Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000143774922007680 Filed on March 30, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.97M	$2.900M	$10.64M
YoY Change	3.11%	50.26%	22.3%
% of Gross Profit
Research & Development	$8.608M	$2.320M	$7.303M
YoY Change	17.87%	373.47%	271.27%
% of Gross Profit
Depreciation & Amortization	$22.53K	$0.00	$22.78K
YoY Change	-1.07%		74.27%
% of Gross Profit
Operating Expenses	$8.608M	$5.230M	$7.303M
YoY Change	17.87%	115.23%	271.27%
Operating Profit	-$19.60M		-$17.96M
YoY Change	9.13%		68.14%
Interest Expense	$5.130K	$0.00	$20.00K
YoY Change	-74.35%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$19.60M	-$5.230M	-$17.94M
YoY Change	9.23%	116.12%	68.45%
Income Tax
% Of Pretax Income
Net Earnings	-$19.60M	-$5.230M	-$17.94M
YoY Change	9.21%	116.12%	68.4%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.44
Diluted Earnings Per Share	-$416.1K	-$131.8K	-$505.1K
COMMON SHARES
Basic Shares Outstanding	47.10M
Diluted Shares Outstanding

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.63M	$27.32M	$27.32M
YoY Change	41.39%	1266.0%	1266.0%
Cash & Equivalents		$27.32M
Short-Term Investments
Other Short-Term Assets	$511.4K	$380.0K	$380.0K
YoY Change	34.57%	123.53%	123.53%
Inventory		$3.010M	$3.010M
Prepaid Expenses
Receivables	$0.00	$127.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$39.14M	$27.70M	$30.72M
YoY Change	27.41%	830.73%	930.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.61K	$39.44K	$40.00K
YoY Change	21.53%	-11.67%	0.0%
Goodwill
YoY Change
Intangibles		$601.6K
YoY Change		22.48%
Long-Term Investments
YoY Change
Other Assets	$8.690K	$3.623M	$10.00K
YoY Change	-13.1%	606.41%	-50.0%
Total Long-Term Assets	$3.722M	$3.663M	$650.0K
YoY Change	472.63%	556.91%	18.18%
TOTAL ASSETS
Total Short-Term Assets	$39.14M	$27.70M	$30.72M
Total Long-Term Assets	$3.722M	$3.663M	$650.0K
Total Assets	$42.86M	$31.37M	$31.37M
YoY Change	36.63%	787.53%	788.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$973.2K	$190.0K	$190.0K
YoY Change	412.21%	-56.82%	-56.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$260.0K	$260.0K
YoY Change	-100.0%	271.43%	271.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.585M	$450.7K	$450.0K
YoY Change	252.29%	-11.74%	-11.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.585M	$450.7K	$450.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.585M	$450.0K	$450.0K
YoY Change	252.29%	-11.76%	-11.76%
SHAREHOLDERS EQUITY
Retained Earnings		-$58.42M
YoY Change		44.33%
Common Stock		$43.12K
YoY Change		123.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.28M	$30.92M	$30.92M
YoY Change
Total Liabilities & Shareholders Equity	$42.86M	$31.37M	$31.37M
YoY Change	36.63%	787.53%	788.67%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$19.60M	-$5.230M	-$17.94M
YoY Change	9.21%	116.12%	68.4%
Depreciation, Depletion And Amortization	$22.53K	$0.00	$22.78K
YoY Change	-1.07%		74.27%
Cash From Operating Activities	-$14.28M	-$3.900M	-$13.94M
YoY Change	2.51%	126.74%	101.41%
INVESTING ACTIVITIES
Capital Expenditures	$31.70K	-$20.00K	$17.56K
YoY Change	80.48%	-80.0%	-47.37%
Acquisitions
YoY Change
Other Investing Activities	-$11.36K	-$2.330M	-$2.210M
YoY Change	-99.49%		176.25%
Cash From Investing Activities	-$83.80K	-$2.340M	-$2.337M
YoY Change	-96.41%	2500.0%	146.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$25.68M		$41.59M
YoY Change	-38.26%		3182.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$25.68M	12.50M	$41.59M
YoY Change	-38.26%	884.25%	3182.02%
NET CHANGE
Cash From Operating Activities	-$14.28M	-3.900M	-$13.94M
Cash From Investing Activities	-$83.80K	-2.340M	-$2.337M
Cash From Financing Activities	$25.68M	12.50M	$41.59M
Net Change In Cash	$11.31M	6.260M	$25.32M
YoY Change	-55.33%	-1259.26%	-483.69%
FREE CASH FLOW
Cash From Operating Activities	-$14.28M	-$3.900M	-$13.94M
Capital Expenditures	$31.70K	-$20.00K	$17.56K
Free Cash Flow	-$14.32M	-$3.880M	-$13.95M
YoY Change	2.61%	139.51%	100.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Location AuditorLocation	Boca Raton, FL
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47874708
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47874708
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43117681
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43117681
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q2	gnpx	Nonvoting To Voting Common Stock Conversion Ratio NonvotingToVotingCommonStockConversionRatio	1	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021Q4	us-gaap	Cash Cash	38628876	USD
CY2020Q4	us-gaap	Cash Cash	27319685	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	127	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	511348	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	384553	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	39140224	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	27704365	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48608	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39441	USD
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	8691	USD
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10741	USD
CY2021Q4	gnpx	Research And Development Assets Noncurrent ResearchAndDevelopmentAssetsNoncurrent	3022403	USD
CY2020Q4	gnpx	Research And Development Assets Noncurrent ResearchAndDevelopmentAssetsNoncurrent	3011042	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	642360	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	601625	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3673454	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3623408	USD
CY2021Q4	us-gaap	Assets Assets	42862286	USD
CY2020Q4	us-gaap	Assets Assets	31367214	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	973195	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	192968	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	612100	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	257756	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1585295	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	450724	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47874	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	43118	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119246970	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89295601	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78017853	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58422229	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	41276991	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	30916490	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42862286	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31367214	USD
CY2021	us-gaap	Revenues Revenues	0	USD
CY2020	us-gaap	Revenues Revenues	0	USD
CY2021	us-gaap	Depreciation Depreciation	22534	USD
CY2020	us-gaap	Depreciation Depreciation	22777	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8607751	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7302923	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10970472	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-17961581	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	5133	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	18811	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10635881	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	19600757	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	17961581	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-19600757	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19595624	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17942770	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47097251
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35522875
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3023545	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	41589529	USD
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	154648	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4091538	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17942770	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	30916490	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25677911	USD
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	156045	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4122169	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19595624	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	41276991	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19595624	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17942770	USD
CY2021	us-gaap	Depreciation Depreciation	22534	USD
CY2020	us-gaap	Depreciation Depreciation	22777	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4278214	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4246186	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-127	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-528	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	126795	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	212837	USD
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-2050	USD
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-10991	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	780226	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-247290	USD
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	354344	USD
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	187329	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14284924	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13935086	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31700.17	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17564	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	40735.32	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	110424	USD
CY2021	gnpx	Payments To Acquire Research And Development Assets PaymentsToAcquireResearchAndDevelopmentAssets	11360.89	USD
CY2020	gnpx	Payments To Acquire Research And Development Assets PaymentsToAcquireResearchAndDevelopmentAssets	2209262	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83796	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2337250	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25677911	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41589529	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25677911	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41589529	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11309191	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25317193	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27319685	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2002492	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38628876	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27319685	USD
CY2018Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	6.6841954	pure
CY2018Q1	gnpx	Capital Stock Shares Authorized CapitalStockSharesAuthorized	210000000
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"/> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Use of Estimates</i></span></b></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	38392885	USD
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	27091596	USD
CY2021Q4	gnpx	Research And Development Assets Current ResearchAndDevelopmentAssetsCurrent	3022403	USD
CY2020Q4	gnpx	Research And Development Assets Current ResearchAndDevelopmentAssetsCurrent	3011042	USD
CY2010Q4	gnpx	State Of Texas Emerging Technology Fund Award Amount StateOfTexasEmergingTechnologyFundAwardAmount	4500000	USD
CY2010	gnpx	Proceeds From State Of Texas Emerging Technology Fund Award ProceedsFromStateOfTexasEmergingTechnologyFundAward	2250000	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670889
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	677912	USD
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	86138
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	156045	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1277743
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1320155	USD
CY2020	gnpx	Stock Issued During Period Shares Warrants Issued StockIssuedDuringPeriodSharesWarrantsIssued	5511599
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2537731	USD
CY2020	gnpx	Stock Issued During Period Shares Exercise Of Cashless Warrants StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants	199630
CY2020	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	51432
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	154648	USD
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47874708
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7476056
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.45
CY2020	gnpx	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	550000
CY2020	gnpx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	2.41
CY2020	gnpx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	44528
CY2020	gnpx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	0.50
CY2020	gnpx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	5826781
CY2020	gnpx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0.47
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2154747
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.37
CY2021	gnpx	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	50000
CY2021	gnpx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	5.29
CY2021	gnpx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	-0
CY2021	gnpx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	0
CY2021	gnpx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2021	gnpx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2204747
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.39
CY2021Q4	gnpx	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	1971412
CY2021Q4	gnpx	Class Of Warrant Or Right Exercisable Exercise Price ClassOfWarrantOrRightExercisableExercisePrice	4.62
CY2020	gnpx	Stock Issued During Period Shares Warrants Issued StockIssuedDuringPeriodSharesWarrantsIssued	5511599
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2537731	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	315182
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8574301
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2519628
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	118507
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670889
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2466529
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	327640
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1277743
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M26D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y21D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5982923
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2466529
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.87
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1277743
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.03
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	327640
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.31
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6844069
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.81
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2519628
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.26
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	670889
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.01
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	118507
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8574301
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.35
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5375507
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.05
CY2021Q4	us-gaap	Other Commitment OtherCommitment	320000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	62.4	USD

Files In Submission

Name	View Source	Status
0001437749-22-007680-index-headers.html	Edgar Link	pending
0001437749-22-007680-index.html	Edgar Link	pending
0001437749-22-007680.txt	Edgar Link	pending
0001437749-22-007680-xbrl.zip	Edgar Link	pending
ex_311628.htm	Edgar Link	pending
ex_311629.htm	Edgar Link	pending
ex_311630.htm	Edgar Link	pending
ex_311631.htm	Edgar Link	pending
ex_351178.htm	Edgar Link	pending
figure1.jpg	Edgar Link	pending
figure2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gnpx-20211231.xsd	Edgar Link	pending
gnpx-20211231_cal.xml	Edgar Link	unprocessable
gnpx-20211231_def.xml	Edgar Link	unprocessable
gnpx-20211231_lab.xml	Edgar Link	unprocessable
gnpx-20211231_pre.xml	Edgar Link	unprocessable
gnpx20211231_10k.htm	Edgar Link	pending
gnpx20211231_10k_htm.xml	Edgar Link	completed
gpx002_800.jpg	Edgar Link	pending
gylze0pdymuz000002.jpg	Edgar Link	pending
gylze0pdymuz000003.jpg	Edgar Link	pending
gylze0pdymuz000004.jpg	Edgar Link	pending
gylze0pdymuz000005.jpg	Edgar Link	pending
gylze0pdymuz000006.jpg	Edgar Link	pending
gylze0pdymuz000010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipeline_v13.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tarcevadata.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GNPX
Genprex Inc Stock $gnpx

2021 Form 10-K Financial Statement

#000143774922007680 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNPX Genprex Inc Stock $gnpx

2021 Form 10-K Financial Statement

#000143774922007680 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNPX
Genprex Inc Stock $gnpx